MedTrace Logo

Prevention of Acute Kidney Injury Through Biomarker-guided Nephrological Intervention

NCT02730637 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2017-12-15

No results posted yet for this study

Summary

This study examines the clinical relevance of early biomarkers to detect and prevent acute kidney injury. High-risk patients for developing acute kidney injury will be screened at initial presentation (emergency department and intensive care unit) for TIMP2xIGFBP7. In case of elevated readings patients will be randomized in two arms: The control group will be treated with standard care, the intervention group will receive an early nephrologic consultation.

Conditions

Interventions

OTHER

Early nephrologist consultation

Sponsors & Collaborators

  • Robert Bosch Medical Center

    lead OTHER

Principal Investigators

  • Martin Kimmel, MD · Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF)

  • Mark Dominik Alscher, MD · Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF)

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-31
Primary Completion
2017-10-31
Completion
2017-11-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02730637 on ClinicalTrials.gov